Results 211 to 220 of about 2,431,689 (244)

The ability of FGF21 to ameliorate signs of non-alcoholic fatty liver disease in mice depends on sex and diet. [PDF]

Vavilovskii Zhurnal Genet Selektsii
Balybina NY, Makarova EN, Jakovleva TV, Kazantseva AY, Bazhan NM.   +4 more
europepmc   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

Current Evidence-Based Clinical Nutritional Approaches in Lipedema: A Scoping Review. [PDF]

Nutr Rev
Atabilen Pınar B, Çelik MN, Altıntaş Başar HB, Ağagündüz D, Karaca OB.   +4 more
europepmc   +1 more source

Therapeutic Potential of Selected Flavonoids as Natural Antidiabetic Agents. [PDF]

Nutrients
Stocerz K, Sokal A, Mruczek P, Kadela-Tomanek M, Ramos P.   +4 more
europepmc   +1 more source

The ketogenic diet in Parkinson's disease: mechanisms, evidence, and clinical practice. [PDF]

Front Nutr
A M, Bai Y, Wang Y, Lv P, Wang S.
europepmc   +1 more source

Consensus Guidelines for Diagnosis and Management of Pyruvate Dehydrogenase Complex Deficiency. [PDF]

J Inherit Metab Dis
Keshavan N, Neugebauer J, Bellusci M, Bertini E, Brown G, Darin N, DeBrosse S, Drexler L, Drexler S, Enns GM, Ganetzky RD, Gilbert K, Larson A, Legi R, Lehman AN, Newby C, Schiff M, Skeath R, Stacpoole PW, Thompson S, Watt E, Wortmann SB, Bedoyan JK, Rahman S.   +23 more
europepmc   +1 more source